← TEVA PHARMACEUTICAL INDUSTRIES LTD
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $21.9b |
$22.4b
+2.20%
|
$18.9b
-15.77%
|
$16.9b
-10.43%
|
$16.7b
-1.35%
|
$15.9b
-4.69%
|
$14.9b
-6.00%
|
$15.8b
+6.17%
|
$16.5b
+4.40%
|
$17.3b
+4.32%
|
$17.3b
+0.32%
|
|
| Cost of Revenue | $10.0b |
$11.8b
+17.18%
|
$10.6b
-10.30%
|
$9.4b
-11.43%
|
$8.9b
-4.47%
|
$8.3b
-7.27%
|
$8.0b
-4.01%
|
$8.2b
+3.12%
|
$8.5b
+3.43%
|
$8.3b
-1.90%
|
$8.2b
-1.06%
|
|
| Gross Profit | $11.9b |
$10.6b
-10.49%
|
$8.3b
-21.85%
|
$7.5b
-9.15%
|
$7.7b
+2.51%
|
$7.6b
-1.71%
|
$7.0b
-8.18%
|
$7.6b
+9.64%
|
$8.1b
+5.48%
|
$8.9b
+10.84%
|
$9.1b
+1.62%
|
|
| Research and Development Expense | $2.1b | $175.0m | $114.0m | — | — | — | $98.0m | — | — | — | $1.7b | |
| Selling, General and Administrative Expense | $1.2b | — | — | — | — | — | — | — | — | — | $4.1b | |
| Amortization of Intangible Assets | — | $1.4b | $1.2b | $1.1b | $1.0b | $802.0m | $732.0m | $616.0m | $588.0m | $581.0m | — | |
| Impairments Restructuring And Others | $699.0m | — | — | — | — | — | — | — | — | — | — | |
| Operating expenses: | ||||||||||||
| Operating Income (Loss) | $2.2b |
($17.5b)
-911.70%
|
($1.6b)
+90.64%
|
($443.0m)
+72.94%
|
($3.6b)
-706.32%
|
$1.7b
+148.04%
|
($2.1b)
-222.32%
|
$433.0m
+120.63%
|
($303.0m)
-169.98%
|
$2.2b
+811.88%
|
$3.2b
+50.25%
|
|
| Other Operating Income (Expense), Net | $2.2b | $1.2b | $291.0m | $76.0m | $40.0m | $98.0m | $107.0m | $49.0m | $14.0m | ($18.0m) | — | |
| Interest Expense | — | $875.0m | $920.0m | $881.0m | $963.0m | $891.0m | $930.0m | $1.0b | $1.0b | $916.0m | $897.0m | |
| Income (Loss) from Equity Method Investments | — | ($3.0m) | ($71.0m) | ($13.0m) | $138.0m | $9.0m | $21.0m | $2.0m | $1.0m | $15.0m | — | |
| Other Income | $2.2b | $1.2b | $291.0m | $76.0m | $40.0m | $98.0m | $107.0m | $49.0m | $14.0m | ($18.0m) | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | — | $1.5b | $1.0b | $542.0m | $947.0m | $126.0m | ($119.0m) | ($767.0m) | ($456.0m) | ($225.0m) | $708.0m | |
| Income before income taxes | $824.0m | — | — | — | — | — | — | — | — | — | $708.0m | |
| Income taxes | $521.0m | — | — | — | — | — | — | — | — | — | — | |
| Current Income Tax Expense (Benefit) | — | $373.0m | $700.0m | $885.0m | $182.0m | $270.0m | $430.0m | $333.0m | $1.1b | — | $12.0m | |
| Income Tax Expense (Benefit) | — | ($1.9b) | ($195.0m) | ($278.0m) | ($168.0m) | $211.0m | ($638.0m) | ($7.0m) | $676.0m | ($180.0m) | $12.0m | |
| Net Income (Loss) Attributable to Parent | $68.0m |
($16.3b)
-24019.12%
|
($2.1b)
+86.78%
|
($999.0m)
+53.53%
|
($4.0b)
-299.40%
|
$417.0m
+110.45%
|
($2.4b)
-664.27%
|
($559.0m)
+76.24%
|
($1.6b)
-193.20%
|
$1.4b
+186.03%
|
$706.0m
-49.93%
|
|
| Net Income (Loss) Available to Common Stockholders, Basic | $68.0m |
($16.5b)
-24401.47%
|
($2.4b)
+85.48%
|
($999.0m)
+58.36%
|
($4.0b)
-299.40%
|
— | — | — | — | — | $706.0m | |
| Net Income (Loss) Attributable to Noncontrolling Interest | — | ($184.0m) | ($322.0m) | ($2.0m) | ($109.0m) | $39.0m | ($53.0m) | ($56.0m) | ($320.0m) | $7.0m | $706.0m | |
| Net Income Attributable to Noncontrolling Interest | ($18.0m) | — | — | — | — | — | — | — | — | — | — | |
| Preferred Stock Dividends, Income Statement Impact | — | $260 | $249 | — | — | — | — | — | — | — | — | |
| Earnings Per Share, Basic | $0.07 | ($16.26) | ($2.35) | ($0.91) | ($3.64) | $0.38 | ($2.12) | ($0.50) | ($1.45) | $1.23 | $0.62 | |
| Earnings Per Share, Diluted | $0.07 | ($16.26) | ($2.35) | ($0.91) | ($3.64) | $0.38 | ($2.12) | ($0.50) | ($1.45) | $1.21 | $0.60 | |
| Basic | $955,000,000.00 | — | — | — | — | — | — | — | — | — | $0.62 | |
| Diluted | $961,000,000.00 | — | — | — | — | — | — | — | — | — | $706,000,000.00 | |
| Common Stock, Dividends, Per Share, Declared | $0.00 | $0.85 | $0.00 | $0.00 | — | — | — | — | — | — | — | |
| Accrued dividends on preferred shares | $261 | — | — | — | — | — | — | — | — | — | — | |
| Weighted Average Number of Shares Outstanding, Basic | — | 1k | 1k | 1.1b | 1.1b | 1.1b | 1.1b | 1.1b | 1.1b | 1.1b | 1.2b | |
| Weighted Average Number of Shares Outstanding, Diluted | — | 1k | 1k | 1.1b | 1.1b | 1.1b | 1.1b | 1.1b | 1.1b | 1.2b | 1.2b | |
| Additional Financial Items | ||||||||||||
| Business Combination, Acquisition Related Costs | — | $105.0m | $13.0m | — | — | — | — | — | — | — | — | |
| Goodwill, Impairment Loss | — | $17.1b | $3.0b | — | $4.6b | $0 | $2.0b | $700.0m | $1.3b | $0 | $973.0m | |
| Legal Settlements And Loss Contingencies | $899.0m | — | — | — | — | — | — | — | — | — | — | |
| Asset Impairment Charges | $900.0m | — | — | — | — | — | — | — | — | — | $973.0m | |
| Financial expenses - net | $1.3b | — | — | — | — | — | — | — | — | — | — | |
| Share in (profits) losses of associated companies net | ($8.0m) | — | — | — | — | — | — | — | — | — | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.